Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Hi Mouton - yes I was aware the EPIC-SR results were finally published (failure of the trial as you know was publicized nearly 2 years prior). I alluded to this in my post listing paxlovid as one of the drugs that failed to show a difference in sustained resolution of the 15 symptom endpoints. Japanese regulators allowed Shionogi to focus on fewer endpoints that were more common especially with current variants for approval.
As I said to Vin it could be when data from the SORPIO-HR trial (ensitrelvir) is made public (hopefully it won't be after a 2 year lag like the PFE trial) a cross trial comparison can be made to gauge EDP-235 relative to ensitrelvir on symptom endpoint.